Hospital
Newaygo County General Hospital Association
Newaygo County General Hospital Association was paid $26.99M by Medicaid between Jan 2018 and Dec 2024, across 274 billing codes. Its largest line is 99284, emergency room visit (serious) — 22% of everything it billed.
33Billing provider infoNEWAYGO COUNTY GENERAL HOSPITAL ASSOCIATION
FREMONT, MI 49412
FREMONT, MI 49412
33aNPI1063836963assigned 02/12/2014
33bProvider typeCritical Access Hospital
28Total paid$26.99M
24GClaims716,900
24DCodes billed274
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Michigan
Rank by total paid#1 of 31
Median peer was paid$6.03M
This provider vs. median4.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CATIGNANI, RYAN controls 15+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 75,590 | $2.02M | |
| 2019 | 65,417 | $1.74M | |
| 2020 | 91,740 | $3.52M | |
| 2021 | 128,621 | $5.07M | |
| 2022 | 124,156 | $4.88M | |
| 2023 | 126,171 | $5.06M | |
| 2024incomplete | 105,205 | $4.71M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 23,912 | 22,566 | $5.92M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 23,659 | 22,484 | $3.74M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 9,626 | 9,100 | $3.56M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.5% | 14,394 | 12,960 | $1.76M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.5% | 5,129 | 4,970 | $938K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.0% | 26,873 | 8,308 | $801K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 2.0% | 7,756 | 7,527 | $530K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.9% | 5,540 | 5,429 | $509K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.6% | 3,909 | 3,863 | $424K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 10,762 | 9,521 | $407K |
| 59025 | Fetal non-stress test | 1.4% | 3,024 | 1,515 | $388K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 7,299 | 7,055 | $354K |
262 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 2,899 | $320K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.2% | 1,679 | $313K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 12,118 | $298K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.0% | 16,234 | $280K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.0% | 2,150 | $271K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,875 | $265K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 4,420 | $227K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 374 | $222K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,854 | $214K |
| 93975 | <1% | 1,385 | $213K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 770 | $200K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 860 | $197K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 5,306 | $181K |
| 76830 | Ultrasound, transvaginal | <1% | 2,169 | $163K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,512 | $152K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,459 | $134K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,608 | $129K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,325 | $123K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 900 | $122K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 411 | $117K |
| 86900 | <1% | 2,684 | $116K | |
| G0378 | Hospital observation service, per hour | <1% | 784 | $111K |
| 97162 | <1% | 1,931 | $110K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 49,522 | $106K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,020 | $106K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 5,193 | $103K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,537 | $103K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,527 | $102K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,498 | $95K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,530 | $85K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 2,478 | $85K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,279 | $81K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 188 | $80K |
| 82947 | <1% | 4,498 | $77K | |
| 80061 | Lipid panel | <1% | 5,942 | $77K |
| 97161 | <1% | 1,255 | $73K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 8,893 | $66K |
| 80053 | Comprehensive metabolic panel | <1% | 31,771 | $64K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,066 | $64K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,357 | $63K |
| 80050 | General health panel | <1% | 2,111 | $59K |
| 73562 | <1% | 2,319 | $58K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,476 | $56K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 86 | $56K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 703 | $56K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 80 | $49K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 351 | $48K |
| 72100 | <1% | 1,089 | $45K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 265 | $45K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,913 | $44K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,186 | $42K |
| 73630 | <1% | 2,503 | $42K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 31,307 | $41K |
| 73030 | <1% | 1,659 | $39K | |
| 73130 | <1% | 2,026 | $34K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 113 | $33K |
| 71250 | <1% | 480 | $33K | |
| 73110 | <1% | 1,699 | $33K | |
| 73610 | <1% | 2,057 | $32K | |
| 93971 | <1% | 465 | $31K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,365 | $30K |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 2,255 | $30K |
| 76642 | <1% | 491 | $27K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 1,387 | $27K |
| 86780 | <1% | 2,796 | $27K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,377 | $25K |
| 70498 | <1% | 103 | $24K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,994 | $24K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,059 | $22K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,410 | $21K |
| 84702 | <1% | 3,378 | $20K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,306 | $20K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 229 | $20K |
| 82728 | <1% | 2,337 | $20K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 50 | $20K |
| 85027 | <1% | 7,592 | $19K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,327 | $17K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,077 | $17K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 587 | $15K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,108 | $15K |
| C9399 | Unclassified drugs or biologicals | <1% | 263 | $15K |
| 76801 | <1% | 219 | $15K | |
| 87653 | <1% | 886 | $15K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 174 | $15K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 260 | $14K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 31 | $14K |
| 72141 | <1% | 65 | $13K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 964 | $12K |
| 73502 | <1% | 405 | $12K | |
| 74018 | <1% | 359 | $12K | |
| 87077 | <1% | 3,393 | $10K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 585 | $10K |
| 87205 | <1% | 5,425 | $10K | |
| 83550 | <1% | 1,816 | $10K | |
| 71271 | <1% | 153 | $9K | |
| 96415 | <1% | 173 | $8K | |
| 84439 | <1% | 1,757 | $8K | |
| 73080 | <1% | 455 | $8K | |
| 87186 | <1% | 2,515 | $8K | |
| 96376 | <1% | 2,761 | $8K | |
| 97163 | <1% | 127 | $8K | |
| 73221 | <1% | 43 | $7K | |
| 83540 | <1% | 1,853 | $7K | |
| 87081 | <1% | 3,299 | $7K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 490 | $7K |
| 82607 | <1% | 901 | $7K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 741 | $7K |
| Q3014 | Telehealth originating site facility fee | <1% | 315 | $7K |
| 76536 | <1% | 97 | $7K | |
| 87340 | <1% | 2,158 | $7K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 182 | $6K |
| 85610 | <1% | 4,283 | $6K | |
| 83880 | <1% | 2,083 | $6K | |
| 76770 | <1% | 82 | $6K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 618 | $6K |
| 83735 | <1% | 6,409 | $5K | |
| 73140 | <1% | 366 | $5K | |
| 77065 | Tomosynthesis, mammo | <1% | 96 | $5K |
| 81001 | <1% | 19,303 | $5K | |
| 82570 | <1% | 2,013 | $4K | |
| 86140 | <1% | 2,323 | $4K | |
| 87070 | <1% | 1,163 | $4K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 312 | $4K |
| 93246 | <1% | 170 | $4K | |
| 84146 | <1% | 279 | $4K | |
| 82950 | <1% | 970 | $3K | |
| 83655 | <1% | 322 | $3K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 186 | $3K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 12 | $3K |
| 96367 | <1% | 51 | $3K | |
| 70486 | <1% | 48 | $3K | |
| 80076 | <1% | 460 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 13,916 | $2K |
| 82043 | <1% | 545 | $2K | |
| 70491 | <1% | 13 | $2K | |
| 82784 | <1% | 300 | $2K | |
| 85652 | <1% | 1,966 | $2K | |
| 84100 | <1% | 1,261 | $2K | |
| 73090 | <1% | 170 | $2K | |
| 0002A | <1% | 57 | $2K | |
| 83690 | <1% | 7,596 | $2K | |
| 86038 | <1% | 230 | $2K | |
| 82746 | <1% | 174 | $2K | |
| 82565 | <1% | 2,657 | $2K | |
| 72040 | <1% | 59 | $2K | |
| 0012A | <1% | 40 | $1K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 26 | $1K |
| 80074 | <1% | 53 | $1K | |
| 87147 | <1% | 608 | $1K | |
| 87808 | <1% | 1,232 | $1K | |
| 0011A | <1% | 40 | $1K | |
| 81025 | <1% | 9,496 | $1K | |
| 84156 | <1% | 1,035 | $1K | |
| 85007 | <1% | 1,039 | $1K | |
| 0001A | <1% | 52 | $1K | |
| 93017 | <1% | 164 | $1K | |
| 77066 | Tomosynthesis, mammo | <1% | 14 | $978.29 |
| 82248 | <1% | 336 | $951.91 | |
| 85730 | <1% | 1,350 | $885.92 | |
| 73590 | <1% | 115 | $875.45 | |
| 84403 | <1% | 50 | $869.48 | |
| 88304 | <1% | 117 | $587.88 | |
| 93242 | <1% | 39 | $572.94 | |
| 86769 | <1% | 25 | $545.08 | |
| 85055 | <1% | 41 | $533.84 | |
| 86762 | <1% | 1,096 | $465.17 | |
| 70496 | <1% | 75 | $416.26 | |
| 88342 | <1% | 12 | $407.96 | |
| 83605 | <1% | 3,924 | $403.83 | |
| 84484 | <1% | 7,004 | $376.84 | |
| 83516 | <1% | 46 | $358.71 | |
| 86200 | <1% | 40 | $341.44 | |
| 85379 | <1% | 1,153 | $314.65 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 15 | $262.83 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,132 | $262.34 |
| 83970 | <1% | 14 | $247.85 | |
| 83615 | <1% | 84 | $212.12 | |
| 86431 | <1% | 57 | $203.48 | |
| 82247 | <1% | 52 | $179.74 | |
| 73564 | <1% | 12 | $175.22 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,372 | $173.44 |
| 84425 | <1% | 12 | $163.63 | |
| 84481 | <1% | 12 | $150.00 | |
| 83001 | <1% | 13 | $140.79 | |
| 12001 | <1% | 180 | $140.77 | |
| 82105 | <1% | 13 | $123.80 | |
| J2704 | Injection, propofol, 10 mg | <1% | 4,483 | $123.46 |
| 87040 | <1% | 399 | $118.50 | |
| 74019 | <1% | 16 | $116.52 | |
| 87109 | <1% | 13 | $111.33 | |
| 87088 | <1% | 32 | $109.33 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,398 | $98.40 |
| 82550 | <1% | 60 | $91.72 | |
| 86850 | <1% | 2,467 | $83.35 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 818 | $77.00 |
| 0296T | <1% | 15 | $66.47 | |
| 80143 | <1% | 283 | $58.84 | |
| 85018 | <1% | 75 | $57.48 | |
| 82077 | <1% | 673 | $55.74 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,570 | $48.59 |
| 84145 | <1% | 129 | $42.40 | |
| 86677 | <1% | 13 | $36.78 | |
| 85014 | <1% | 30 | $26.69 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,301 | $23.00 |
| A9270 | Non-covered item or service | <1% | 2,222 | $22.66 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,216 | $18.08 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,641 | $16.37 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,689 | $15.26 |
| 80179 | <1% | 209 | $14.91 | |
| 87807 | <1% | 148 | $10.53 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,856 | $10.45 |
| 86308 | <1% | 12 | $8.20 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,151 | $6.54 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,436 | $6.40 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,492 | $6.09 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,324 | $5.98 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,477 | $5.60 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,501 | $5.48 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,855 | $4.92 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 10,404 | $0.03 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 2,032 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 193 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 527 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 461 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 1,413 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 175 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 232 | $0.00 |
| A9573 | Injection, gadopiclenol, 1 ml | 0% | 94 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 112 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 17 | $0.00 |
| 87503 | 0% | 93 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 386 | $0.00 |
| 86901 | 0% | 134 | $0.00 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 64 | $0.00 |
| 76377 | 0% | 136 | $0.00 | |
| 91301 | 0% | 85 | $0.00 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 13 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 24 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 35 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 30 | $0.00 |
| 12002 | 0% | 14 | $0.00 | |
| J8501 | Aprepitant, oral, 5 mg | 0% | 12 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 25 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 91 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 491 | $0.00 |
| 90715 | 0% | 471 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 1,593 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 2,558 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 63 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 238 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 231 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 87 | $0.00 |
| 29125 | 0% | 80 | $0.00 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 115 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 28 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 27 | $0.00 |
| 76942 | 0% | 26 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 83 | $0.00 |
| 91300 | 0% | 111 | $0.00 | |
| 82800 | 0% | 14 | $0.00 | |
| 82010 | 0% | 28 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 42 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCATIGNANI, RYAN (VP FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Spectrum Health Primary Care Partners | Grand Rapids, MI | $219.58M |
| Spectrum Health Primary Care Partners | Grand Rapids, MI | $14.49M |
| Spectrum Health Primary Care Partners | Grand Rapids, MI | $2.34M |
| Mecosta County Medical Center | Big Rapids, MI | $1.55M |
| Lakeland Community Hospital Watervliet | Watervliet, MI | $910K |
| Newaygo County General Hospital Association | Fremont, MI | $841K |
| Pennock Hospital | Hastings, MI | $719K |
| Spectrum Health Primary Care Partners | Muskegon, MI | $710K |
| Spectrum Health Primary Care Partners | Holland, MI | $319K |
| Memorial Medical Center of West Michigan | Ludington, MI | $268K |
| Spectrum Health Primary Care Partners | Hudsonville, MI | $152K |
| Reed City Hospital Corporation | Reed City, MI | $115K |
| Spectrum Health Primary Care Partners | Wyoming, MI | $106K |
| Spectrum Health Primary Care Partners | Grand Rapids, MI | $73K |
| Zeeland Community Hospital | Zeeland, MI | $4K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.